Abstract
Web ExclusivesMarch 2023Annals Consult Guys - Could This Patient Have Heyde Syndrome?FREEHoward H. Weitz, MD, Geno J. Merli, MD, Theodore Earl Warkentin, MD, and Nicholas J. Ruggiero II, MDHoward H. Weitz, MDThomas Jefferson University, Philadelphia, Pennsylvania (H.H.W., G.J.M., N.J.R.)Search for more papers by this author, Geno J. Merli, MDThomas Jefferson University, Philadelphia, Pennsylvania (H.H.W., G.J.M., N.J.R.)Search for more papers by this author, Theodore Earl Warkentin, MDMcMaster University, Hamilton, Ontario, Canada (T.E.W.)Search for more papers by this author, and Nicholas J. Ruggiero II, MDThomas Jefferson University, Philadelphia, Pennsylvania (H.H.W., G.J.M., N.J.R.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W22-0016 CME/MOC SectionsSupplemental MaterialAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is Heyde syndrome? In this episode, the Annals Consult Guys and their guests describe the syndrome and current thinking about appropriate management of patients with gastrointestinal bleeding associated with it.For more videos from and information on Annals Consult Guys, visit go.annals.org/ConsultGuys. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Thomas Jefferson University, Philadelphia, Pennsylvania (H.H.W., G.J.M., N.J.R.)McMaster University, Hamilton, Ontario, Canada (T.E.W.)Disclosures: Drs. Merli and Weitz report that they have no financial relationships or interests to disclose. Dr. Warkentin reports grants or contracts from Werfen; royalties or licenses from Informa and Wolters Kluwer; consulting fees from Aspen Canada/Aspen Global, CSL Behring, Ergomed, Paradigm Pharmaceuticals, Octapharma, Veralox Therapeutics, and Werfen; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Werfen; payment for expert testimony from Medical-Legal; and participation on a data safety monitoring or advisory board from Octapharma and Paradigm Pharmaceuticals. Dr. Ruggiero reports grants or contracts for the Bard True Balloon Study and the Ancora Heart Corcinch Trial, and payment for expert testimony from the U.S. government and Post & Schell. All relevant financial relationships have been mitigated. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=W22-0016.Editors' Disclosures: The editors have no relevant financial relationships to disclose. Individual forms may be viewed at www.annals.org/editorsdisclosures. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Current IssueMarch 2023Volume 176, Issue 3 ePublished: 21 March 2023 Issue Published: March 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.Loading ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.